GlassScriptPhysician profile
Angela Wong
NPI 1689383697
$3,585.05
in general payments reported to CMS, 2019-2025
19 companies · $3,554 in 2025
The $3,554 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $31.22 · 2025: $3,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $945.08 | 2024-2025 | Tremfya |
| Abbvie INC. | $473.14 | 2025 | |
| Genzyme Corporation | $419.28 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.38 | 2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $270.61 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $194.40 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $177.74 | 2025 | Entyvio, Eohilia |
| Pfizer INC. | $163.74 | 2025 | |
| Madrigal Pharmaceuticals | $139.38 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $116.91 | 2025 | Terlivaz |
| Lilly USA, LLC | $116.60 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $47.21 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $40.01 | 2025 | Suflave, Sutab |
| Celltrion USA INC. | $31.44 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $26.10 | 2025 | Vowst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $25.85 | 2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $23.68 | 2025 | Dupixent |
| Novo Nordisk INC | $21.94 | 2025 | Wegovy |
| Evoke Pharma, INC. | $16.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.